Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ly317615.hcl
1. 170364-57-5
2. Ly317615
3. Enzastaurin (ly317615)
4. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione
5. Ly-317615
6. 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
7. Db102
8. Uc96g28eqf
9. Ly 317615
10. Chembl300138
11. Db-102
12. Dsstox_cid_24029
13. Dsstox_rid_80101
14. Dsstox_gsid_44029
15. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)-piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione
16. 1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-
17. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione
18. 3-(1-methyl-1h-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl}-1h-pyrrole-2,5-dione
19. Enzastaurin [inn]
20. Cas-170364-57-5
21. Unii-uc96g28eqf
22. 3-(1-methyl-1h-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione
23. Le-0014
24. Enzastaurin [mi]
25. Enzastaurin [usan:inn]
26. Enzastaurin,ly317615
27. Enzastaurin [usan]
28. Enzastaurin; Ly317615
29. Enzastaurin [who-dd]
30. Ly317615 - Enzastaurin
31. Schembl678748
32. Gtpl5693
33. Dtxsid5044029
34. Chebi:91368
35. Amy7827
36. Bcpp000241
37. Hms3265m05
38. Hms3265m06
39. Hms3265n05
40. Hms3265n06
41. Hms3654a13
42. Hms3748e03
43. Bcp02703
44. Ex-a1055
45. Who 8426
46. Zinc1494900
47. Tox21_113367
48. Bdbm50128285
49. Mfcd11040980
50. Nsc767124
51. Nsc800096
52. S1055
53. Akos015994764
54. Tox21_113367_1
55. Ac-5900
56. Bcp9000648
57. Ccg-264797
58. Cs-0132
59. Db06486
60. Nsc-767124
61. Nsc-800096
62. Sb16481
63. Ncgc00238452-01
64. Ncgc00238452-02
65. Ncgc00238452-03
66. Ncgc00238452-11
67. Hy-10342
68. Db-064781
69. Ft-0667873
70. Sw219797-1
71. Ec-000.2315
72. 364e575
73. J-510442
74. Q5381479
75. Brd-k79404599-001-01-0
76. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-1h-pyrrole-2,5-
77. 3-(1-methyl-1h-indol-3-yl)-4-[1-(1-pyridin-2-ylmethyl-piperidin-4-yl)-1h-indol-3-yl]-pyrrole-2,5-dione
78. 3-(1-methyl-1h-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl}-2,5-dihydro-1h-pyrrole-2,5-dione
Molecular Weight | 515.6 g/mol |
---|---|
Molecular Formula | C32H29N5O2 |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | 515.23212518 g/mol |
Monoisotopic Mass | 515.23212518 g/mol |
Topological Polar Surface Area | 72.2 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 974 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through multiple mechanisms. Preclinical data indicate it may reduce the cell's ability to reproduce (cell proliferation), increase the natural death of the tumor cells (apoptosis), and inhibit tumor- induced blood supply (angiogenesis). Enzastaurin has been shown to inhibit signaling through the PKC-B and PI3K/AKT pathways. These pathways have been shown to be activated in a wide variety of cancers. In addition to glioblastoma, enzastaurin is also being studied in multiple other tumor types, including non-Hodgkin's lymphoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer, and mantle cell lymphoma.
ABOUT THIS PAGE
A Enzastaurin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Enzastaurin, including repackagers and relabelers. The FDA regulates Enzastaurin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Enzastaurin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Enzastaurin supplier is an individual or a company that provides Enzastaurin active pharmaceutical ingredient (API) or Enzastaurin finished formulations upon request. The Enzastaurin suppliers may include Enzastaurin API manufacturers, exporters, distributors and traders.
Enzastaurin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Enzastaurin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Enzastaurin GMP manufacturer or Enzastaurin GMP API supplier for your needs.
A Enzastaurin CoA (Certificate of Analysis) is a formal document that attests to Enzastaurin's compliance with Enzastaurin specifications and serves as a tool for batch-level quality control.
Enzastaurin CoA mostly includes findings from lab analyses of a specific batch. For each Enzastaurin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Enzastaurin may be tested according to a variety of international standards, such as European Pharmacopoeia (Enzastaurin EP), Enzastaurin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Enzastaurin USP).
LOOKING FOR A SUPPLIER?